17 January 2024
EMA/CAT/38816/2024
Human Medicines Division

Committee for Advanced Therapies (CAT)

Minutes of the meeting on 06-08 December 2023

Chair: Ilona Reischl; Vice-Chair: Kieran Breen

Disclaimers

Some of the information contained in these minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CAT meeting reports once the procedures are finalised.

Of note, these minutes are a working document primarily designed for CAT members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

Table of contents

1. Introduction

1.1. Welcome and declarations of interest of members, alternates and experts

The Chairperson opened the meeting by welcoming all participants. The meeting was held in-person with some members connected remotely.

In accordance with the Agency's policy on handling of declarations of interests of scientific committees' members and experts, based on the declarations of interest submitted by the Committee members, alternates and experts and on the topics in the agenda of the current meeting, the Committee Secretariat announced the restricted involvement of some Committee members, alternates and experts for concerned agenda topics.

Participants were asked to declare any changes, omissions or errors to their declared interests and/or additional restrictions concerning the matters for discussion. No new or additional interests or restrictions were declared. Restrictions applicable to this meeting are captured in the List of participants included in the minutes.

Discussions, deliberations and voting took place in full respect of the restricted involvement of Committee members and experts in line with the relevant provisions of the Rules of Procedure. All decisions, recommendations and advice were agreed by consensus, unless otherwise specified.

1.2. Adoption of agenda

The CAT agenda for 06-08 December 2023 meeting was adopted.

CAT was informed on the actions following the FDA safety communication on the risk of secondary malignancies in patients treated with CAR-T cells.

1.3. Adoption of the minutes

The CAT minutes for 30-31 October 2023 meeting were adopted.

2. Evaluation of ATMPs

2.1. Opinions

2.1.1. Exagamglogene autotemcel - PRIME - Orphan - EMEA/H/C/005763

Vertex Pharmaceuticals (Ireland) Limited; Treatment of transfusion-dependent β-thalassemia and sickle cell disease

Scope: Opinion

Action: for adoption

List of outstanding issues adopted on 08.09.2023 and 31.10.2023. List of questions adopted on 17.05.2023.

The Rapporteur presented the outcome of the assessment of the responses to the last list of outstanding issues. Feedback was provided from the BWP discussion. On the clinical part of the application, the Rapporteur presented the agreed indications and the proposed specific obligations and commitments.

CAT adopted a positive opinion recommending granting a conditional marketing authorisation to Casgevy for the indications: transfusion dependent β-thalassemia and severe sickle cell disease.

2.2. Oral explanations

No items

2.3. Day 180 list of outstanding issues

No items

2.4. Day 120 list of questions

No items

2.5. Day 80 assessment reports

No items

2.6. Update on ongoing initial applications

No items

2.7. New applications

2.7.1. Beremagene geperpavec - PRIME - Orphan - EMEA/H/C/006330

Krystal Biotech Netherlands B.V.; Treatment of patients from birth with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene

Scope: Timetable for assessment

Action: for adoption

The assessment timetable was adopted.

2.8. Withdrawal of initial marketing authorisation application

No items

2.9. Re-examination of initial application procedures under Article 9(2) of Regulation No. 726/2004

No items

2.10. Companion diagnostics

2.10.1. Initial consultation

No items

2.10.2. Follow-up consultation

No items

2.11. Type II variations and variations of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

2.11.1. Breyanzi - lisocabtagene maraleucel / lisocabtagene maraleucel - EMEA/H/C/004731/II/0018/G

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Concetta Quintarelli

Scope: Quality, opinion

Action: for adoption

Request for supplementary information adopted on 15.06.2023.

The opinion was adopted.

2.11.2. Breyanzi - lisocabtagene maraleucel / lisocabtagene maraleucel - EMEA/H/C/004731/II/0026/G

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Concetta Quintarelli

Scope: Quality, opinion

Action: for adoption

Request for supplementary information adopted on 08.09.2023.

The opinion was adopted.

2.11.3. Breyanzi - lisocabtagene maraleucel / lisocabtagene maraleucel - EMEA/H/C/004731/II/0032

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Concetta Quintarelli

Scope: Quality, request for supplementary information

Action: for adoption

The request for supplementary information was adopted.

2.11.4. CARVYKTI - ciltacabtagene autoleucel - Orphan - EMEA/H/C/005095/II/0021

Janssen-Cilag International NV

Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Jo Robays

Scope: Indication, request for supplementary information

Extension of indication to include treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 1 prior therapy, including an IMiD (Immunomodulatory imide drugs (IMiDs)) and a PI (proteasome inhibitors), have demonstrated disease progression on or after the last therapy and are refractory to lenalidomide for CARVYKTI, based on interim results from study MMY3002 listed as a specific obligation (SOB/006) in the Annex II. This is an ongoing, Phase 3, randomised, open-label, multicentre study to determine whether treatment with cilta-cel provides an efficacy benefit compared to standard therapy in participants with relapsed and lenalidomide-refractory multiple myeloma. As a consequence, sections 4.1, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 4.1 of the RMP has also been submitted. In addition, the MAH took the opportunity to update Annex II of the product information. As part of the application the MAH is requesting a 1-year extension of the market protection.

Action: for adoption

Request for supplementary information adopted on 08.09.2023.

The Rapporteur presented the outcome of the assessment of the responses to the request for supplementary information.

The second request for supplementary information were adopted.

2.11.5. Hemgenix - etranacogene dezaparvovec - Orphan - EMEA/H/C/004827/II/0009/G

CSL Behring GmbH

Rapporteur: Silke Dorner

Scope: Quality, opinion

Action: for adoption

Request for supplementary information adopted on 31.10.2023.

The opinion was adopted.

2.11.6. Libmeldy - atidarsagene autotemcel - Orphan - EMEA/H/C/005321/II/0021

Orchard Therapeutics (Netherlands) B.V.

Rapporteur: Emmely de Vries

Scope: Quality, opinion

Action: for adoption

The opinion was adopted.

2.11.7. Strimvelis - autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence - Orphan - EMEA/H/C/003854/II/0039

Fondazione Telethon ETS

Rapporteur: Sol Ruiz

Scope: Quality, opinion

Action: for adoption

The opinion was adopted.

2.11.8. Yescarta - axicabtagene ciloleucel - Orphan - EMEA/H/C/004480/II/0065

Kite Pharma EU B.V.

Rapporteur: Jan Mueller-Berghaus

Scope: Clinical, opinion

Update of section 4.8 of the SmPC in order to add Infusion Related Reactions to the list of adverse drug reactions (ADRs) with frequency Common, based on a cumulative review of the MAH safety database, clinical trials and post-marketing data. The Package Leaflet is updated accordingly.

Action: for adoption

The opinion was adopted.

2.12. Extension applications

No items

2.13. Other Post-Authorisation Activities

2.13.1. Breyanzi - lisocabtagene maraleucel / lisocabtagene maraleucel - EMEA/H/C/004731/REC/016

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Concetta Quintarelli

Scope: Quality

Action: for adoption

The outcome of the quality recommendation was agreed.

2.13.2. CARVYKTI - ciltacabtagene autoleucel - Orphan - EMEA/H/C/005095/REC/014

Janssen-Cilag International NV

Rapporteur: Jan Mueller-Berghaus

Scope: Quality

Action: for adoption

The outcome of the quality recommendation was agreed.

2.13.3. CARVYKTI - ciltacabtagene autoleucel - Orphan - EMEA/H/C/005095/REC/015

Janssen-Cilag International NV

Rapporteur: Jan Mueller-Berghaus

Scope: Quality

Action: for adoption

The outcome of the quality recommendation was agreed.

2.13.4. Holoclar - ex vivo expanded autologous human corneal epithelial cells containing stem cells - Orphan - EMEA/H/C/002450/R/0058

Holostem Terapie Avanzate s.r.l.

Rapporteur: Egbert Flory, Co-Rapporteur: Concetta Quintarelli, PRAC Rapporteur: Rhea Fitzgerald

Scope: 1 year Renewal of Marketing Authorisation

Action: for adoption

Request for supplementary information adopted on 06.10.2023.

The Rapporteur presented the outcome of the assessment of the responses to the request for supplementary information.

CAT adopted the renewal of the marketing authorisation and the conversion of the conditional marketing authorisation to a standard marketing authorisation for Holoclar.

2.13.5. ROCTAVIAN - valoctocogene roxaparvovec - Orphan - EMEA/H/C/005830/MEA/003.2

BioMarin International Limited

Rapporteur: Violaine Closson Carella

Scope: Pharmacovigilance, adoption of conclusions

MAH response to MEA 003.1 as adopted in July 2023: Impact of ROCTAVIAN on fertility, general toxicity, teratology and germline transmission in females of childbearing potential.

Action: for adoption

The Rapporteur presented the assessment of the responses from the applicant. The post-authorisation measure is not yet fulfilled.

2.13.6. Tecartus - brexucabtagene autoleucel - Orphan - EMEA/H/C/005102/ANX/011.1

Kite Pharma EU B.V.

Rapporteur: Jan Mueller-Berghaus

Scope: Clinical & Pharmacovigilance, request of supplementary information

Protocol of Study No. KTE-EU-474-6644 [Long-term, non-interventional study of recipients of Tecartus for treatment of adult patients with relapsed or refractory acute lymphoblastic leukaemia (ALL)]. MAH Responses ANX 011 as adopted in March 2023.

Action: for adoption

The Rapporteur presented the assessment of the responses from the applicant. The proposed protocol for the study No. KTE-EU-474-6644 is not yet considered acceptable. A second request for supplementary information was adopted.

2.13.7. Upstaza – eladocagene exuparvovec - EMEA/H/C/005352/S/0017

PTC Therapeutics International Limited

Rapporteur: Maura O'Donovan, Co-Rapporteur: Maria Luttgen

Scope: Annual reassessment, request for supplementary information

Action: for adoption

The Rapporteur presented the outcome of assessment. The status of the two studies identified in the specific obligations was presented. The quality Annex II condition remains outstanding. A request for supplementary information was adopted.

CAT was also updated on the registry for study PTC-AADC-MA-406.

2.14. GMP and GCP inspections requests

No items

3. Certification of ATMPs

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

3.1. Opinion

No items

3.2. Day 60 Evaluation Reports

No items

3.3. New Applications

No items

4. Scientific Recommendation on Classification of ATMPs

Deadline for submission of new requests: 23.11.2023. New requests will appear in version 1 of the agenda.

Timetable:

-Start of the procedure:	18.12.2023
-EMA Coordinator's draft report:	03.01.2024
-CAT Coordinator's comments:	11.01.2024
-Revised scientific recommendation:	12.01.2024
-CAT's discussion of scientific recommendation:	19.01.2024

4.1. New requests – Appointment of CAT Coordinator

4.1.1. Allogeneic expanded natural killer cells

For the treatment of acute myeloid leukaemia

Scope: Appointment of CAT Coordinator and adoption of timetable

Action: for adoption

The CAT coordinator was appointed.

4.1.2. Autologous tissue generated in the human body (in vivo) through the foreign body reaction

For tissue augmentation

Scope: Appointment of CAT Coordinator and adoption of timetable

Action: for adoption

The CAT coordinator was appointed.

4.1.3. Dendritic cells activated by lysate of circulating tumour cells

For the treatment of solid tumours in metastatic stage

Scope: Appointment of CAT Coordinator and adoption of timetable

Action: for adoption

The CAT coordinator was appointed.

4.1.4. Autologous T Lymphocytes engineered with nanoparticles with curcumin incapsulated

For the treatment of melanoma

Scope: Appointment of CAT Coordinator and adoption of timetable

Action: for adoption

The CAT coordinator was appointed.

4.2. Day 30 ATMP scientific recommendation

No items

4.3. Day 60 revised scientific recommendation (following list of questions)

4.3.1. Allogeneic peripheral blood-derived HSPC, Treg cells and Tcon cells

Prevention of moderate to severe chronic graft-vs.-host disease and/or death in patients with acute leukaemias and in patients with myelodysplastic syndrome (MDS) undergoing HLA-matched allogeneic hematopoietic stem cell transplant (alloHCT)

Scope: ATMP scientific recommendation

Action: for adoption

The CAT coordinator presented the additional information provided by the applicant. The report will be updated in line with the CAT conclusion and send to the European Commission for comments by 5 January 2024.

4.4. Finalisation of procedure

4.4.1. Live, freeze-dried, genetically modified Lactococcus lactis strain, engineered to secrete human interleukin-10 (hIL-10) and a deamidated, human leukocyte antigen (HLA)-DQ2 restricted, 33-mer alpha-gliadin peptide (dDQ2)

Treatment of celiac disease

Scope: European Commission raised no comments. ATMP scientific recommendation

Action: for adoption

The classification report was adopted. The product does fulfil the definition of a gene therapy medicinal product as provided in Article 2(1) of Regulation (EC) No 1394/2007.

4.4.2. Autologous lymphocytes enriched in activated natural killer cells

Cancer

Scope: European Commission raised no comments. ATMP scientific recommendation

Action: for adoption

The classification report was adopted. The product does fulfil the definition of a somatic cell therapy medicinal product as provided in Article 2(1) of Regulation (EC) No 1394/2007.

4.4.3. Umbilical cord blood leukocyte concentrate containing cord blood stem cells

Hypoxic-ischaemic encephalopathy

Scope: European Commission raised no comments. ATMP scientific recommendation

Action: for adoption

The classification report was adopted. The product does fulfil the definition of a somatic cell therapy medicinal product as provided in Article 2(1) of Regulation (EC) No 1394/2007.

4.4.4. Umbilical cord blood leukocyte concentrate containing cord blood stem cells

Cerebral palsy

Scope: European Commission raised no comments. ATMP scientific recommendation

Action: for adoption

The classification report was adopted. The product does fulfil the definition of a somatic cell therapy medicinal product as provided in Article 2(1) of Regulation (EC) No 1394/2007.

4.4.5. DNA plasmid expressing short hairpin RNA (shRNA) against lytic origin of DNA replication of Epstein Barr Virus (EBV) messenger RNA (mRNA)

Treatment of EBV infected patients

Scope: European Commission raised no comments. ATMP scientific recommendation

Action: for adoption

The classification report was adopted. The product does fulfil the definition of a gene therapy medicinal product as provided in Article 2(1) of Regulation (EC) No 1394/2007.

4.4.6. DNA plasmid expressing short hairpin RNA (shRNA) against BCL2 anti-apoptotic messenger RNA (mRNA)

Treatment of cancer patients

Scope: European Commission raised no comments. ATMP scientific recommendation

Action: for adoption

The classification report was adopted. The product does fulfil the definition of a gene therapy medicinal product as provided in Article 2(1) of Regulation (EC) No 1394/2007.

4.5. Follow-up and guidance

No items

5. Scientific Advice

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

5.1. New requests - appointment of CAT Rapporteurs

5.1.1. Ongoing scientific advice procedures - Appointment of CAT Peer Reviewers

Timetable:

- Start of procedure at SAWP:	27-30.11.2023
- Appointment of CAT Peer Reviewers:	06-08.12.2023
- SAWP first reports:	02.01.2024
- CAT Peer Reviewer comments (NC/C)	05.01.2024
- CAT Peer Reviewer comments (Q)	10.01.2024
- Discussion at SAWP:	08-11.01.2024
- Discussion at CAT and feedback to SAWP:	17-19.01.2024

5.1.2. Scientific advice procedures starting at the next SAWP meeting

Timetable:

- Start of procedure at SAWP:	08.01.2024
- Appointment of CAT Peer Reviewers:	17-19.01.2024
- SAWP first reports:	29.01.2024
- CAT Peer Reviewer comments (NC/C):	02.02.2024
- CAT Peer Reviewer comments (Q)	07.02.2024
- Discussion at SAWP:	05-08.02.2024
- Discussion at CAT and feedback to SAWP:	14-16.02.2024

5.2. Procedures discussed at SAWP – 1st reports, D40 JRs, LoIs

5.3. Finalisation of D70 procedures – feedback from the discussion meeting

No items

5.4. Final Advice Letters for procedures finalised the previous month

6. Pre-Authorisation Activities

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

6.1. Paediatric investigation plans

No items

6.2. ITF briefing meetings in the field of ATMPs

6.3. Priority Medicines (PRIME) – Eligibility requests

6.3.1. Month 0 - Start of the procedure

Timetable for assessment	
Procedure start:	27-30.11.2023
SAWP recommendation:	11.01.2024
CAT recommendation:	19.01.2024
CHMP adoption of report and final recommendation:	25.01.2024

6.3.2. Month 1 – Discussion of eligibility

6.3.3. Month 2 – Recommendation of eligibility

No items

6.3.4. Ongoing support

No items

7. Organisational, regulatory and methodological matters

7.1. Mandate and organisation of the CAT

7.1.1. CAT membership

Action: for information

The Chair welcomed Anna Baráné Gilicze, as the new member for Hungary.

7.1.2. Mandates for the current joint CHMP-CAT memberships

Scope: Mandates for the current joint CHMP-CAT memberships will expire on 17.12.2023

Action: for information

Information was provided on the appointment by CHMP of the joint CHMP-CAT members.

The joint members who are CHMP co-opted members confirmed the nomination of their alternates.

7.1.3. Vote by proxy

None

7.1.4. Onboarding Programme for CAT members and alternates

Scope: Revised Onboarding Programme

CAT: Ilona Reischl

Action: for adoption

EMA presented the final onboarding programme, following the comments received by the following CAT members: Kieran Breen, Emmely de Vries, Kerstin Sollerbrant, Azra Selimovic, Suzana Vidic and Mencia de Lemus Belmonte. The final onboarding programme was adopted and will now be made available to all new members and alternates joining CAT.

The CAT onboarding programme will also be sent to CHMP for their awareness.

7.1.5. CAT Strategic Review & Learning meeting (SRLM) under the Spanish presidency, 25-27 October 2023 Madrid (Spain)

CAT: Sol Ruiz, Marcos Timon

Scope: Presentations from the SRLM

Action: for information

The presentations from the SRLM meeting of 25-27 October are available .

7.1.6. CAT Strategic Review & Learning meeting (SRLM) under the Belgian presidency

CAT: Claire Beuneu

Scope: Date for the upcoming SRLM: 15-17 May 2024

Action: for information

The date of the SRLM under the Belgian presidency was noted.

7.2. Coordination with EMA Scientific Committees

No items

7.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

7.3.1. Reflection paper on the use of real-world data to generate real-world evidence in non-interventional studies

Presenter: Olaf Klungel

Scope: Presentation of the methodology working group (MWP) draft Reflection Paper on real-world evidence

Action: for information

Following the presentation of the draft reflection paper (RP), CAT made some comments. The scope of the RP needs to be clarified in order not to give the impression that real-world evidence generation in non-interventional studies can be used instead of conducting clinical trials. It was proposed that the document is also shared with the clinical trial coordination group (CTCG). The following CAT members will provide comment on the reflection paper: Ilona Reischl and Rozalina Kulaksazova (deadline: 12 January 2024).

7.4. Cooperation with the EU regulatory network

7.4.1. Feedback from EDQM

CAT: Catherine Milne (EQDM)

Scope: Planned consultation of EMA and NCAs to explore a certification system for rapid microbial methods

Action: for information

Catherine Milne provided information on the plan of EDQM to consult NCA and EMA on the possibility of using the EDQM certification scheme for alternative microbial methods (certification towards Ph.Eur. general chapter 5.1.6). The concept for certification of alternative microbial methods was presented. EDQM plans to organise a webinar first, followed by a workshop in Q1 2024 to discuss the concept.

CAT indicated that safety methods should be validated prior to first-in-human trial. So even if the Ph.Eur is not applicable to investigational medicinal products, the proposed certifications scheme of alternative microbial methods should be open to manufacturers of investigational medicinal products. It was proposed to also involve the clinical trial coordination group (CTCG) in the consultation.

7.4.2. Support to member states for the assessment of ATMP marketing authorisation applications

CAT: Ilona Reischl

Scope: Group of experienced ATMP quality assessors from BWP/CAT

Action: for agreement

CAT agreed with the nomination of the experience ATMP quality assessors from CAT.

EMA was asked to investigate if an expert in statistical analysis related to quality/manufacturing development could be included in this group.

7.5. Cooperation with international regulators

7.5.1. ICH Cell and Gene Therapy Discussion Group

CAT: Jan Müller-Berghaus, Niamh Curran

Scope: To provide an overview of the proposed ICH Cell and Gene Therapy Discussion Group's workplan and proposed deliverables

Action: for information

Jan Müller-Berghaus provided a detailed feedback on the activities of the ICH Cell and Gene Therapy Discussion Group, and the workplan and proposed deliverables of this group. The workplan and deliverables will go to the ICH management committee for endorsement.

The CAT and BWP members supporting the EU representatives in the group were agreed.

Regular updates of the activities of the ICH Cell and Gene Therapy Discussion Group will be provided to CAT.

7.5.2. ICH Q5A 'Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin'

Rapporteur/Coordinator: Johannes Blumel (DE-PEI)

Scope: To provide an overview of the key changes contemplated in this revision

Action: for information

The main revisions of the ICH Q5A guideline were presented: viral vector-based products that are amenable to viral clearance without negative impact on the product are also included in this revision. Cell therapies remain outside of the scope of this guideline.

7.6. CAT work plan

7.6.1. Update on real-world evidence (RWE) studies to support EMA scientific committees

Scope: quarterly update on Real World Evidence, including DARWIN EU®

Action: for information

EMA provided the quarterly update on Real World Evidence, including DARWIN EU®. This includes the list of new data partners planned to be onboarded in DARWIN EU, the progress of DARWIN EU, in-house studies and funded studies, information on the DARWIN EU pharmacogenetic pilot studies and upcoming events (launch of the first 2 modules of the Pharmacoepidemiology/RWE curriculum for regulators, EMA-HMA Catalogues of data sources and non-interventional studies, Multistakeholder workshops on patient registries on 12-13.02.2024).

Alessandra Renieri agreed to be involved in future case studies in the pharmacogenetic-epidemiology field.

7.6.2. CAT work plan for 2024

CAT: Ilona Reischl

Scope: Draft CAT work plan for 2024

Action: for discussion

The work plan, updated following the discussions in the September CAT meeting was presented. CAT was informed that the draft work plan was also presented at the recent Scientific Coordination Board meeting, during which the joint activities with other Committees were discussed and agreed.

CAT agreed with the CAT work plan topics: additional CAT members agreed to contribute to the different topics.

The CAT workplan will be finalised for adoption at the January 2024 meeting. It is noted that the activities for 2024 for the work plan topic on the use of real-world evidence for regulatory decision making will still have to be drafted (see agenda point 7.6.1, also linked to the actions that are originating from the SMA study).

7.7. Planning and reporting

No items

7.8. Others

7.8.1. Artificial intelligence for neoantigen-based personalized treatments against cancer

Scope: Lecture

Action: for information

A presentation was given by colleagues from the Paul-Ehrlich-Institute on the use of artificial intelligence used for neoantigen prediction.

8. Any other business

No items

Date of next CAT meeting:

17-19 January 2024

9. List of participants

Including any restrictions with respect to involvement of members / alternates / experts following evaluation of declared interests for the 06-08 December 2023 meeting.

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Ilona Reischl	Chair	Austria	No interests declared	
Silke Dorner	Member	Austria	No interests declared	
Corina Spreitzer	Alternate	Austria	No restrictions applicable to this meeting	
Claire Beuneu	Member	Belgium	No interests declared	
Olga Kholmanskikh	Alternate	Belgium	No interests declared	
Rozalina Kulaksazova	Member	Bulgaria	No interests declared	
Azra Selimovic	Member	Croatia	No interests declared	
Petra Sokol	Alternate	Croatia	No interests declared	
Petr Soukup	Member	Czechia	No interests declared	
Kristyna Rehorova Hradilkova	Alternate	Czechia	No interests declared	
Ebru Karakoc Madsen	Member	Denmark	No restrictions applicable to this meeting	
Toivo Maimets	Member	Estonia	No interests declared	
Pille Saalik	Alternate	Estonia	No interests declared	
Heli Suila	Member	Finland	No interests declared	
Violaine Closson Carella	Member	France	No interests declared	
Jan Mueller-Berghaus	Member (CHMP co-opted member)	Germany	No interests declared	
Egbert Flory	Alternate (to CHMP representative)	Germany	No interests declared	
Maria Gazouli	Member	Greece	No interests declared	
Balázs Sarkadi	Alternate	Hungary	No restrictions applicable to this meeting	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Maura O'Donovan	Member	Ireland	No interests declared	
Concetta Quintarelli	Member	Italy	No interests declared	
Barbara Bonamassa	Alternate	Italy	No restrictions applicable to this meeting	
Una Riekstina	Member	Latvia	No interests declared	
Raimondas Benetis	Alternate (to CHMP representative)	Lithuania	No interests declared	
Nancy De Bremaeker	Member	Luxembourg	No interests declared	
John J. Borg	Member (CHMP member)	Malta	No interests declared	
Anthony Samuel	Alternate (to CHMP representative)	Malta	No interests declared	
Emmely de Vries	Member	Netherlands	No interests declared	
Tineke van den Hoorn	Alternate	Netherlands	No interests declared	
Rune Kjeken	Member	Norway	No participation in discussion, final deliberations and voting on:	5.2.1.
Marcin Kolakowski	Alternate	Poland	No interests declared	
Maria Isabel Borba Vieira	Alternate (to CHMP representative)	Portugal	No interests declared	
Katarina Kollarova	Member	Slovakia	No interests declared	
Margareta Fogelová	Alternate	Slovakia	No interests declared	
Suzana Vidic	Alternate	Slovenia	No restrictions applicable to this meeting	
Marcos Timón	Alternate (to CHMP representative)	Spain	No interests declared	
Maria Luttgen	Member	Sweden	No participation in discussion, final deliberations and voting on:	5.4.4.
Charlotte Anderberg	Alternate	Sweden	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Bernd Gansbacher	Alternate	Clinicians' Representative	No interests declared	
Alessandra Renieri	Alternate	Clinicians' Representative	No restrictions applicable to this meeting	
Kerstin Sollerbrant Melefors	Member	Patients' Representative	No interests declared	
Kieran Breen	Member (Vice-Chair)	Patients' Representative	No interests declared	
Catherine Milne	Observer/Alternate	EDQM	No interests declared	
Torbjorn Callreus	Expert	Malta	No interests declared	
Johannes Hendrikus Ovelgonne	Member	Netherlands	No interests declared	
Renate König	Observer	Germany	No declaration of interests needed	
Liam Childs	Expert	Germany	No interests declared	
Olaf Klungel	Expert	Netherlands	No interests declared	
Juliane Rau	Expert	Germany	No interests declared	
Attila Sebe	Expert	Germany	No interests declared	
Denise Tischner	Expert	Germany	No restrictions applicable to this meeting	
Matthias Renner	Expert	Germany	No restrictions applicable to this meeting	
Antonella Isgrò	Expert	Italy	No interests declared	
Beate Mosl	Expert	Germany	No interests declared	
Federico De Angelis	Expert	Italy	No interests declared	
Johannes Blumel	Expert	Germany	No interests declared	
Filip Josephson	Expert	Sweden	No interests declared	
Nina Hessvik Pettersen	Expert	Norway	No interests declared	
Annemarie den Harder	Expert	Netherlands		
Boje Kvorning Pires Ehmsen	Expert	Denmark	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
A representative from the European Commission attended the meeting				
Meeting run with support from relevant EMA staff				

10. Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

For a list of acronyms and abbreviations, see:

List of abbreviations used in EMA human medicines scientific committees and CMDh documents, and in relation to EMA's regulatory activities

Evaluation of ATMPs (section 2)

This section lists applications for marketing authorisations of new Advanced Therapy Medicinal Products (ATMPs) that are to be discussed by the Committee. It also lists Post-authorisation activities (section 2.11-2.13) and any ATMP related inspection requests (section 2.14).

New applications (sections 2.1. to 2.9.)

Section 2.1 is for ATMPs nearing the end of the evaluation and for which the CAT is expected to adopt a draft **opinion** at this meeting on whether marketing authorisation should be granted. Once adopted, the CAT opinion is transmitted to the CHMP for final adoption. The CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU. More information on the evaluation of ATMPs can be found here.

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:



The assessment of an application for a new medicine takes up to 210 'active' days. This active evaluation time is interrupted by at least one 'clock-stop' during which time the applicant prepares the answers to questions from the CAT. The clock stop happens after day 120 and may also happen after day 180, when the CAT has adopted respectively a **Day 120 list of questions** (section 2.4) or a List of outstanding issues to be addressed by the company, which is listed in the agenda under sections 2.7 (**Ongoing evaluation procedures** (section 2.3). Section 2.6 also includes the CAT discussions at any other timepoint of the evaluation procedure of new applications.

Oral explanation (section 2.2.)

Prior to adoption of the CAT opinion, marketing authorisation applicants are normally invited to the CAT plenary meeting to address questions raised by the Committee.

Oral explanations normally relate to ongoing applications, but they can also relate to any other issue for which the CAT would like to discuss with company representatives in person.

New applications (section 2.7.)

In this section, information is included on upcoming marketing authorisation applications for ATMPs, as well as information on appointment of Rapporteurs for new ATMP applications.

Withdrawal of applications (section 2.8.)

This section includes information on marketing authorisation applications that are withdrawn by the applicant. Applicants may decide to withdraw applications at any stage during the assessment and a CAT opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 (section 2.9.)

This section lists applications for new marketing authorisation for ATMPs for which the applicant has requested a re-examination of the opinion previously issued by the CHMP. Similar to the initial evaluation of a marketing authorisation of an ATMP, CAT will adopt a draft re-examination opinion, which is transmitted to the CHMP for final adoption.

Companion diagnostics (section 2.10)

This section lists applications for initial and follow-on consultation of companion diagnostics.

Post-authorisation activities (section 2.11-2.13.)

Section 2.11 lists type II variations, including extension of indication applications and re-examination procedures for type II variations for which the applicant has requested re-examination of the opinion previously issued by the CHMP. Section 2.12 list extension application according to Annex I of Reg. 1234/2008 and section 2.13 includes all other post-authorisation activities concerning authorised ATMPs that are not covered elsewhere in the agenda such as post-authorisation measures, annual reassessments, 5-year renewals, supply shortages, qualify defects. Issues that have been discussed at the previous meeting of the PRAC, the EMA's committee responsible for evaluating and monitoring safety issues for medicines, will also be included here.

GMP and GCP Inspections Issues (section 2.14.)

This section lists inspections that are undertaken for ATMPs. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

Certification of ATMPs (section 3)

This section includes the scientific evaluation by the CAT of quality and non-clinical data that small and medium-sized enterprises have generated at any stage of the ATMP development process. More information on the ATMP certification procedure can be found here.

Scientific Recommendation on Classification of ATMPs (Section 4)

This section includes the scientific recommendation by the CAT on whether medicines based on genes, cells or tissues meet the scientific criteria that define ATMPs. More information on the ATMP classification procedure, including the outcomes of finalised classifications, can be found here.

Scientific Advice (section 5)

This section includes all scientific advice given to companies during the development of an ATMP. Information related to the number of ATMP related scientific advices discussed by CAT can be found in the CAT Monthly reports. Further information on SAWP can be found here.

Pre-Authorisation (section 6)

Paediatric Investigation Plan (PIP)

This section includes the discussion of an ATMP before a formal application for marketing authorisation is submitted. These cases refer for example to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation: in case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

CAT contributes to the evaluation of a Paediatric Investigation Plan (PIPs) for ATMPs by the Paediatric Committee. These PIPs are included in this section of the Agenda.

ITF Briefing meeting in the field of ATMPs

This section refers to briefing meetings of the Innovation Task Force and International co-operations activities of the CAT

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes of meetings with applicants developing ATMPs and of other ITF meetings of interest to the CAT are included in this section of the agenda. Further information on the ITF can be found here.

Priority Medicines (PRIME)

This section includes the new requests for eligibility to PRIME for ATMPs under development, the discussions in CAT of these eligibility requests and the final recommendations for eligibility of ATMPs adopted by CHMP.

CAT will appoint one of its members as the CAT sponsor for each new ATMP eligibility request who will lead the CAT discussion based on the recommendation from the SAWP.

Organisational, regulatory and methodological matters (section 7)

This section includes topics related to regulatory and procedural guidance, CAT workplan, CAT meeting organisation (including CAT membership), planning and reporting, co-ordination with other committees, working parties and scientific advisory groups.

Furthermore, this section refers to the activities of the CAT drafting groups developing scientific guidelines for gene therapy medicinal products and for cell-based medicinal products, cooperation within the EU regulatory network and international regulators as well as direct interaction with interested parties. It also includes topics of scientific interest for the Committee that are not directly related to the work of the CAT drafting groups or CAT associated working parties.

Any other business (section 8)

This section is populated with miscellaneous topics not suitable under the previous headings.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/